Exhibit 5.1
April 1, 2024
Gritstone bio, Inc.
5959 Horton Street, Suite 300
Emeryville, CA 94608
Ladies and Gentlemen:
As counsel to Gritstone bio, Inc., a Delaware corporation (the “Company”), we deliver this opinion with respect to certain matters in connection with the offering by the Company of up to (a) 8,333,333 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), (b) pre-funded warrants (the “Initial Pre-Funded Warrants”) to purchase up to 13,334,222 shares of Common Stock at an exercise price of $0.0001 per share (such shares issuable upon exercise of the Initial Pre-Funded Warrants, the “Initial Pre-Funded Warrant Shares”), and (c) accompanying warrants (the “Accompanying Warrants”) to purchase up to 21,667,555 shares of Common Stock (the “Accompanying Warrant Shares”) or pre-funded warrants (the “Accompanying Pre-Funded Warrants” and together with the Initial Pre-Funded Warrants and the Accompanying Warrants, the “Warrants”) to purchase up to 21,667,555 shares of Common Stock (the “Accompanying Pre-Funded Warrant Shares” and collectively with the Initial Pre-Funded Warrant Shares and the Accompanying Warrant Shares, the “Warrant Shares” and collectively with the Shares and Warrants, the “Securities”) issued pursuant to that certain Underwriting Agreement (the “Underwriting Agreement”), dated as of April 1, 2024, by and between the Company and Cowen and Company, LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein. The Shares, Warrants and Warrant Shares were registered pursuant to the Registration Statement on Form S-3 (File No. 333-263455) filed by the Company with the Securities and Exchange Commission (the “Commission”) on March 10, 2022 and declared effective on May 6, 2022 (the registration statement at the time it was declared effective, including the documents or portions thereof incorporated by reference therein, as modified or superseded as described therein, and the information deemed to be a part thereof pursuant to Rule 430B under the Securities Act of 1933, as amended (the “Securities Act”), the “Registration Statement”) under the Securities Act, including the prospectus dated March 10, 2022 included therein (the “Base Prospectus”) as supplemented by the final prospectus supplement dated April 1, 2024, filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”). The offering of the Securities by the Company pursuant to the Registration Statement, the Prospectus and the Underwriting Agreement is referred to herein as the “Offering.” This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly herein with respect to the issue of the Securities.
As to matters of fact relevant to the opinions rendered herein, we have examined such documents, certificates and other instruments which we have deemed necessary or advisable, including a certificate addressed to us and dated the date hereof executed by the Company (the “Opinion Certificate”). We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties or to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of the Company or the rendering of the opinions set forth below. We have not considered parol evidence in connection with any of the agreements or instruments reviewed by us in connection with this letter.